Updownsite.com

Keyword Analysis & Research: koselugo


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
koselugo1.010.68679728

Keyword Research: People who searched koselugo also searched

Keyword CPC PCC Volume Score
koselugo1.190.4806165
koselugo selumetinib1.360.3159225
koselugo price0.520.7823168
koselugo package insert0.860.3655236
koselugo ema0.60.1328541
koselugo precio1.40.4188777
koselugo dosing1.370.691472
koselugo uspi1.770.182732
koselugo indication0.260.6802342
koselugo copay card1.280.179985
koselugo pi0.510.8353475
koselugo fachinfo1.480.6253722
koselugo fda label1.890.5532038
koselugo fachinformation0.810.4712369

Search Results related to koselugo on Search Engine

  • KOSELUGO

    koselugo.com

    https://koselugo.com/

    WEBWhat is Koselugo? Koselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. It is not known if Koselugo is safe and effective in children under 2 years of age.

    DA: 84 PA: 4 MOZ Rank: 83 Up or Down: Up

  • Selumetinib - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Selumetinib

    WEBSelumetinib (INN), sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. It is taken by mouth.

    DA: 97 PA: 61 MOZ Rank: 21 Up or Down: Up

  • Koselugo: Uses, Dosage, Side Effects, Warnings - Drugs.com

    drugs.com

    https://www.drugs.com/koselugo.html

    WEBMay 30, 2023 · Koselugo is a prescription medicine used to treat neurofibromatosis (a genetic disorder that causes tumors to develop on the nerves) in children at least 2 years old. Neurofibromatosis may cause tumors in the brain or spinal cord, learning disabilities, tumors on or under the skin, or bone deformities.

    DA: 74 PA: 40 MOZ Rank: 17 Up or Down: Up

  • FDA Approves First Therapy for Children with Debilitating and

    fda.gov

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-children-debilitating-and-disfiguring-rare-disease

    WEBApril 10, 2020. Today, the U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1...

    DA: 19 PA: 26 MOZ Rank: 26 Up or Down: Up

  • KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients ... - Merck

    merck.com

    https://www.merck.com/news/koselugo-selumetinib-approved-by-fda-for-pediatric-patients-two-years-and-older-with-neurofibromatosis-type-1-and-symptomatic-inoperable-plexiform-neurofibromas/

    WEBApr 13, 2020 · First Medicine Approved to Treat This Rare and Debilitating Condition. KENILWORTH, N.J.-- (BUSINESS WIRE)--. AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved the kinase inhibitor KOSELUGO (selumetinib) …

    DA: 6 PA: 67 MOZ Rank: 19 Up or Down: Up

  • Frequently Asked Questions | Koselugo™ (selumetinib) 10mg

    koselugo.com

    https://koselugo.com/faqs/

    WEBWhat is Koselugo? Koselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. It is not known if Koselugo is safe and effective in children under 2 years of age.

    DA: 50 PA: 36 MOZ Rank: 88 Up or Down: Up

  • NF1 PN Treatment for Pediatric Patients | KOSELUGO® …

    koselugohcp.com

    https://koselugohcp.com/

    WEBLearn about KOSELUGO® (selumetinib), a treatment for neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients 2 years of age and older.

    DA: 38 PA: 69 MOZ Rank: 13 Up or Down: Up

  • Koselugo | European Medicines Agency

    europa.eu

    https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo

    WEBApr 23, 2021 · Overview. Koselugo is a medicine used to treat plexiform neurofibromas, benign (non-cancerous) tumours along the nerves, when they cause symptoms and cannot be removed by surgery in children from 3 years of age with neurofibromatosis type 1 (NF1).

    DA: 42 PA: 68 MOZ Rank: 74 Up or Down: Up

  • Koselugo Oral: Uses, Side Effects, Interactions, Pictures ... - WebMD

    webmd.com

    https://www.webmd.com/drugs/2/drug-179157/koselugo-oral/details

    WEBGeneric Name (S): selumetinib-vitamin e tpgs. Uses. Selumetinib is used to treat a type of tumor that grows on nerves ( neurofibromatosis type 1 ). Selumetinib belongs to a class of drugs known as...

    DA: 35 PA: 86 MOZ Rank: 100 Up or Down: Up

  • What is KOSELUGO? | KOSELUGO® (selumetinib) 10 mg & 25 …

    koselugo.com

    https://koselugo.com/about-koselugo/

    WEBKoselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. It is not known if Koselugo is safe and effective in children under 2 years of age.

    DA: 4 PA: 75 MOZ Rank: 100 Up or Down: Up